<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118963</url>
  </required_header>
  <id_info>
    <org_study_id>Reform</org_study_id>
    <nct_id>NCT00118963</nct_id>
  </id_info>
  <brief_title>Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes</brief_title>
  <official_title>Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control With Oral Hypoglycaemic Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <brief_summary>
    <textblock>
      Aim:

      The United Kingdom Prospective Diabetes Study (UKPDS) showed a reduction in cardiovascular
      events in obese patients with type-2-diabetes treated with metformin compared with other
      hypoglycaemic treatments with no difference in glycemic control between treatments. Non-obese
      patients with type-2-diabetes are usually treated with insulin-secretagogues or insulin when
      diet fails. Since non-obese patients with type-2-diabetes also carry a high risk of
      cardiovascular events, the use of metformin for this sub-group of patients might be more
      beneficial. Moreover, when insulin-treatment is initiated ongoing oral hypoglycaemic agents
      (OHA) are often continued, but in non-obese patients with type-2 diabetes little evidence
      exist for choosing the optimal class of OHA to be combined with insulin. The aim of the
      project is therefore to investigate the effect of metformin vs. an insulin-secretagogue
      (repaglinide) in combination with insulin on glycemic control and non-glycemic cardiovascular
      risk-factors in non-obese patients with type-2-diabetes, uncontrolled on diet alone.

      Methodology:

      Single-center, double-blind, double-dummy, randomized, parallel study involving 100 non-obese
      (BMI 27 kg/m2 or lower) patients with type-2-diabetes investigating the effect of treatment
      with metformin vs. repaglinide each in combination with biphasic insulin (Insulin-aspart
      30/70, BIAsp30) for a period of 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After four months run-in with repaglinide plus metformin combination-therapy, patients with
      HemoglobinA1c â‰¥6.5% will be randomized (baseline=0 month) to repaglinide 2 mg thrice-daily or
      metformin 1g twice-daily, both in combination with BIAsp30 (30% insulin-aspart; 70%
      protaminated insulin-aspart) (6U once-daily, pre-dinner) for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic control (HbA1c).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Home monitored plasma-glucose profiles</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-dose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-glycemic cardiovascular risk factors: 24h blood-pressure measurement</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h urinary albumin excretion-rate.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting and postprandial 5-point-profiles of total-cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, free fatty acids, p-glucose, c-peptide and insulin after a standard test-meal</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of endothelial dysfunction, inflammation and fibrinolysis including Small-dense-LDL, Lp(a) and Apo B100, von Willebrand-factor, ICAM, VCAM, selectin, endothelin, Amadori-protein, CRP, fibrinogen, IL-6, TNF-alfa, ADMA, PAI- and t-PA-activity</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BIAsp30 plus Metformin plus Placebo-Repaglinide. Double-Masked and randomized. Duration: 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BIAsp30 plus Repaglinide plus Placebo-Metformin. Double-masked and randomized. Duration: 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Run-in period of four months duration with Repaglinide 6 mg daily plus Metformin 2000 mg daily. No masking of interventions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Tablets of 500 mg; 1000 mg two times daily.</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin BIAsp30 (Novolog 70/30)</intervention_name>
    <description>Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>Tablets of 1 mg; Dosage: 2 mg three times daily.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Metformin</intervention_name>
    <description>Tablets corresponding to 500 mg; two tablets two times daily.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Repaglinide</intervention_name>
    <description>Tablet corresponding to 1 mg; two tablets three times daily.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-obese patients (BMI &lt; 27 kg/m2)

          -  Type 2 diabetes

          -  Age 40 years or older

          -  HbA1c = 6.5% or higher at baseline.

        Exclusion Criteria:

          -  No known contraindications for either of the study-drugs (known allergy to the
             study-drugs; heart-, liver- or kidney-failure)

          -  Pregnancy

          -  Other serious physical or mental illnesses with a life-shortening prognosis.

          -  Drug or alcohol abuse.

          -  Weight-loss of more than 5 kg during the last 6 month prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan A Vaag, M.D. Chief Physician</last_name>
    <role>Study Chair</role>
    <affiliation>Steno Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2005</study_first_submitted>
  <study_first_submitted_qc>July 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2005</study_first_posted>
  <last_update_submitted>December 5, 2008</last_update_submitted>
  <last_update_submitted_qc>December 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

